DNA encoding a protease-activated receptor 3
Disclosed are cDNAs and genomic DNAs encoding protease-activated receptor 3 (PAR3) from mouse and human, and the recombinant polypeptides expressed from such cDNAs. The recombinant receptor polypeptides, receptor fragments and analogs expressed on the surface of cells are used in methods of screening candidate compounds for their ability to act as agonists or antagonists to the effects of interaction between thrombin and PAR3. Agonists are used as therapeutics to treat wounds, thrombosis, atherosclerosis, restenosis, inflammation, and other thrombin-activated disorders. Antagonists are used as therapeutics to control blood coagulation and thereby treating heart attack and stroke. Antagonists mediate inflammatory and proliferative responses to injury as occur in normal wound healing and variety of diseases including atherosclerosis, restenosis, pulmonary inflammation (ARDS) and glomerulosclerosis. Antibodies specific for a protease-activated receptor 3 (or receptor fragment or analog) and their use as a therapeutic are also disclosed.
Latest The Regents of the University of California Patents:
- METHODS TO ENHANCE EFFICACY OF COMBINED TARGETING OF IMMUNE CHECKPOINT AND MAPK PATHWAYS
- COMPOSITIONS AND METHODS OF MAKING POLYMERIZING NUCLEIC ACIDS
- METHODS FOR IMPROVING PROTEIN DELIVERY TO PLANT CELLS BY BIOLISTICS
- Membranes for enhancing rates of water dissociation and water formation
- Virus-like nanoparticles for oral delivery
Claims
1. Substantially pure DNA having the nucleotide sequence selected from the group consisting of SEQ ID NO:1, or degenerate variants thereof, and encoding the amino acid sequence of SEQ ID NO:3; SEQ ID NO:2, or degenerate variants thereof encoding an amino acid sequence comprising the amino acid sequence of SEQ ID NO:3; SEQ ID NO:4, or degenerate variants thereof encoding the amino acid sequence of SEQ ID NO:6; and SEQ ID NO:5, or degenerate variants thereof encoding an amino acid sequence comprising the amino acid sequence of SEQ ID NO:6.
2. A vector comprising the DNA of claim 1.
3. A cell comprising the vector of claim 2.
4. A substantially pure DNA sequence complementary to a DNA sequence selected from the group consisting of SEQ ID NO:1, or degenerate variants thereof, and encoding the amino acid sequence of SEQ ID NO:3; SEQ ID NO:2, or degenerate variants thereof encoding an amino acid sequence comprising the amino acid sequence of SEQ ID NO:3; SEQ ID NO:4, or degenerate variants thereof encoding the amino acid sequence of SEQ ID NO:6; and SEQ ID NO:5, or degenerate variants thereof encoding an amino acid sequence comprising the amino acid sequence of SEQ ID NO:6.
WO 95/19436 | July 1995 | WOX |
- Amatrude III, T.T., et al. (1991) "G.alpha.16, a G protein .alpha.subunit specifically expressed in hematopoietic cells," Proc. Natl. Acad. Sci. 88:5587-91. Connolly, A., et al. (1996) "Role of the thrombin receptor in development and evidence for a second receptor," Nature 381:516-519. Ishii, K., et al. (1993) "Kinetics of thrombin receptor cleavage on intact cells," J. Biol. Chem. 268:9780-9786. Ishii, K., et al. (1995) "Determinants of thrombin receptor cleavage," J. Biol. Chem. 270:16435-16440. Julius, D., et al. (1988) "Molecular characterization of a functional cDNA encoding the serotonin 1c receptor" Science 241:558-564. Liu, L., et al. (1991) "The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity," J. Biol. Chem. 266:16977-16980. Mathews, I.I., et al. (1994) "Crystallographic structures of thrombin complexed with thrombin receptor peptides: Existence of expected and novel binding modes," Biochem. 33:3266-3279. Nonevicz, T., et al. (1996) "Thrombin receptor activating mutations," J. Biol. Chem. 271:702-706. Nystedt, S., et al. (1994) "Molecular cloning of a potential proteinase activated receptor," Proc. Natl. Acad. Sci. USA, 91:9208-9212. Scarborough, R.M., et al. (1992) "Tethered ligand agonist peptides," J. Biol. Chem. 267:13146-13149. Soifer, S.J., et al. (1993) "Disparate temporal expression of the prothrombin and thrombin receptor genes during mouse development," Am. J. Pathol. 144:60-69. Vu, T.-K.H., et al. (1991) "Molecular cloning of a functional thrombin receptor reveals a novel protcolytic mechanism of receptor activation," Cell 64:1057-1068. Vu, T.-K.H., et al. (1991) "Domains specifying thrombin-receptor interaction," Nature 353:674-677.
Type: Grant
Filed: Oct 30, 1996
Date of Patent: Apr 6, 1999
Assignee: The Regents of the University of California (Oakland, CA)
Inventors: Shaun R. Coughlin (Tiburon, CA), Hiroaki Ishihara (San Francisco, CA), Andrew Connolly (San Francisco, CA)
Primary Examiner: Lila Feisee
Assistant Examiner: Michael Pak
Law Firm: Bozicevic & Reed LLP
Application Number: 8/742,440
International Classification: C12N 1512; C12N 1563; C12N 510;